Study links higher risk of type 2 diabetes due to early onset of menstruation

Scientific results published in the journal Menopause quotes Diabetes as a global health concern which will allegedly affect about 693 million people by 2045. Extensive research on the topic already indicated how diet and exercise can influence the risk of type 2 diabetes. However, new research indicates that body mass index (BMI) may also be involved in the onset of diabetes.

According to reports, in 2015, type 2 diabetes mellitus affected nearly 8.8% people aged between 20 and 79 globally. The number was expected to increase to 10.4% by 2040. Intensive global research directed towards identification of disease determinants is helping towards preventing further development. Research also draws efforts into knowing the influence of various environmental and lifestyle factors, in addition to physiologic factors.

Based on the latest study published in Menopause, the journal of The North American Menopause Society (NAMS), proved that women with early menstruating developed a higher risk of type 2 diabetes. The result was examined on the basis of analysis of more than 15,000 postmenopausal women in China. Each year delay in menarche age was known to be correlated with a 6% lower risk of type 2 diabetes.

The latest study has provided evidence in an increased risk. Moreover, it also suggests that BMI partially mediates the association and the proportion of the effect is noted to be 28%.

“Early menarche is associated with an increased risk of type 2 diabetes in rural Chinese women and is partially mediated by BMI: the Henan Rural Cohort Study.”

“This study of rural Chinese women indicates that the average age of menarche is delayed relative to western countries at 16.1 years and is linked with lower risk of type 2 diabetes. Earlier onset of menses (14 y) was associated with diabetes in later life, likely driven by adult BMI. Other factors such as nutrition and BMI in childhood may also play a role in this association,” according to study results quoted by Dr. Stephanie Faubion, NAMS medical director.